Stock No. 013591: The C3(1)-TAg transgenic strain is a model for the study of multistage oncogenesis in the prostate and mammary glands.
Of note, a subline was identified with transgene rearrangement/deletion to only one copy (or a partial copy) in the original chromosome 6 locus - resulting in retained tolerance to SV40 TAg but no spontaneous cancer phenotype. The new subline, called C3(1)/TAg-REAR, is available as Stock No. 030386.
Jeffrey E Green, National Cancer Institute, National Institutes of Health (NIH/NCI)
Cryopreservation Cryopreservation, TJL
Genetic Background | Generation |
---|---|
?+pN2F5
|
Allele Type |
---|
Transgenic (Inserted expressed sequence) |
Starting at:
$255.00 Domestic price for female 4-week |
333.51 Domestic price for breeder pair |
The C3(1)/TAg founder line C originally contained ~six transgene copies at a single locus in the telomeric portion of chromosome 6 (which contains the Ki-ras proto-oncogene) - resulting in multistage oncogenesis in prostate and mammary gland. The published details are described in detail below.
Male hemizygous transgenic mice develop prostatic hyperplasia in early life that progresses to adenoma or adenocarcinoma in about half of the animals which survive longer 7 months of age. Some transgenic male hemizygotes develop adenocarcinomas of the urethral/periurethral and bulbourethral glands (10-20% of hemizygous males) and submandibular gland (10% of hemizygous males 8 months of age). In female transgenic mice, the transgene is expressed primarily in the distal mammary ductal
epithelium and terminal ductal lobular unit. Female hemizygous animals generally develop mammary intraepithelial neoplasia with similarities to DCIS by 3 months of age with subsequent development of mammary adenocarcinoma by 6 months of age in 100% of the animals. About 10-15% of hemizygous female mice develop lung metastases. Direct invasion of adjacent lymph nodes, skeletal muscle, salivary glands and tissues as well as mammary tumor metastases in liver, adrenal and heart have also been observed. Bone, brain and regional lymph node metastases have not been observed. Tumors of the sweat glands have been observed in both male and female transgenic animals. The phenotype for this transgene has been most extensively studied in the FVB/N background. While homozygotes are viable and fertile, pups born to homozygous mothers need foster mothers because of lactation difficulties.
Of note, in 2016, 6-7 week old mice from this Jackson Laboratory colony were observed to display gait abnormalities. While the expected phenotype of this transgenic line might conceivably lead to gait abnormalities, the expected pathology in the eccrine sweat glands of the foot pads seems not to be the cause. Histologic analysis indicates that these mice have significant changes in the cartilage of the stifle and hip joints, with variable pathology that is sometimes severe. Cartilage is severely thickened and hyperplastic, with multifocal acellular regions and multifocal cartilage necrosis and loss.
Further, routine screening of the donating investigator’s C3(1)/TAg founder line C colony identified female transgenic mice that retained tolerance to SV40 TAg but did not develop the expected phenotype (mammary tumors) - a result of transgene rearrangement/deletion to only one copy (or a partial copy) in the original chromosome 6 locus. The newer subline, called C3(1)/TAg-REAR, is available as Stock No. 030386.
A transgenic construct containing the simian virus 40 early-region transforming sequences under the regulatory control of the rat prostatic steroid binding protein C3(1) gene was microinjected into FVB/N fertilized oocytes. Founder line c was subsequently established. Upon arrival at The Jackson Laboratory, the mice were crossed to FVB/NJ (Stock No. 001800) at least once to establish the colony.
Expressed Gene | TAg, SV40 large T-antigen, SV40 |
---|---|
Site of Expression |
Allele Name | transgene insertion c, Jeffrey E Green |
---|---|
Allele Type | Transgenic (Inserted expressed sequence) |
Allele Synonym(s) | C3(1)/SV40; C3(1)/SV40T; C3(1)/T antigen (Tag); C3(1)/T(AG); C3(1)/TAg; C3(1)-SV40 T antigen; C3(1)-Tag; C3Tag; C3-TAg; Large T; Tg(Scgb2a2-TAg)cJeg |
Gene Symbol and Name | Tg(C3-1-TAg)cJeg, transgene insertion c, Jeffrey E Green |
Gene Synonym(s) | |
Promoter | C3(1), C3(1), rat |
Expressed Gene | TAg, SV40 large T-antigen, SV40 |
Strain of Origin | FVB/N |
Chromosome | UN |
Molecular Note | This transgene contains the rat prostatic binding protein C3 promoter (Pbpc3) and the wild-type allele of the SV40 large tumor antigen (TAg) gene. Founder c carried 6 copies of the transgene. Founders f, g, i, j, k, and l were also generated. Two transgenic lines (c and l) were produced. |
Mutations Made By | Jeffrey Green, National Cancer Institute, National Institutes of Health (NIH/NCI) |
When maintaining a live colony, transgene carrier mice may be bred with wildtype mice from the colony or with FVB/NJ (Stock No. 001800) mice. While homozygotes are viable and fertile, pups born to homozgyous mothers need foster mothers because of lactation difficulties. Female hemizygous animals generally develop mammary intraepithelial
neoplasia with similarities to DCIS by 3 months of age with subsequent
development of mammary adenocarcinoma by 6 months of age in 100% of the
animals. Male hemizygous transgenic mice develop prostatic hyperplasia in early
life that progresses to adenoma or adenocarcinoma in about half of the
animals which survive longer 7 months of age.
When using the C3(1)-TAg , C3(1)/Tag mouse strain in a publication, please cite the originating article(s) and include JAX stock #013591 in your Materials and Methods section.
Service/Product | Description | Price |
---|---|---|
Hemizygous or Non carrier for Tg(C3-1-TAg)cJeg |
Frozen Mouse Embryo | FVB-Tg(C3-1-TAg)cJeg/JegJ Frozen Embryo | $2595.00 |
Frozen Mouse Embryo | FVB-Tg(C3-1-TAg)cJeg/JegJ Frozen Embryo | $2595.00 |
Frozen Mouse Embryo | FVB-Tg(C3-1-TAg)cJeg/JegJ Frozen Embryo | $3373.50 |
Frozen Mouse Embryo | FVB-Tg(C3-1-TAg)cJeg/JegJ Frozen Embryo | $3373.50 |
Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.
The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project. We do not guarantee breeding performance and therefore suggest that investigators order more than one breeding pair to avoid delays in their research.
What information were you hoping to find through your search?
How easy was it to find what you were looking for?
We may wish to follow up with you. Enter your email if you are happy for us to connect and reachout to you with more questions.
Please Enter a Valid Email Address
Thank you for sharing your feedback! We are working on improving the JAX Mice search. Come back soon for exciting changes.